| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | AA-COCF3 | CTRPv2 | pan-cancer | AAC | 0.009 | 0.8 |
| mRNA | RDEA119 | FIMM | pan-cancer | AAC | 0.044 | 0.8 |
| mRNA | IPR-456 | CTRPv2 | pan-cancer | AAC | 0.0096 | 0.8 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | -0.0088 | 0.8 |
| mRNA | XMD14-99 | GDSC1000 | pan-cancer | AAC | -0.0082 | 0.8 |
| mRNA | SB-431542 | CTRPv2 | pan-cancer | AAC | -0.0094 | 0.8 |
| mRNA | prima-1 | CTRPv2 | pan-cancer | AAC | -0.0078 | 0.8 |
| mRNA | Tamoxifen | GDSC1000 | pan-cancer | AAC | -0.0083 | 0.8 |
| mRNA | CBB-1007 | CTRPv2 | pan-cancer | AAC | -0.013 | 0.8 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0082 | 0.8 |